Annual report
2796.TEDINET S100P3F9
Period2021-06-01 → 2022-05-31
Filed2022-08-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥51.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales |
| Revenue | ¥52.3bn | 2020-06-01 → 2021-05-31 | Cons. | Net sales |
| Revenue | ¥51.0bn | 2019-06-01 → 2020-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.7bn | 2018-06-01 → 2019-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥54.6bn | 2017-06-01 → 2018-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.5bn | 2021-06-01 → 2022-05-31 | Cons. | Operating income |
| Operating income | ¥1.2bn | 2020-06-01 → 2021-05-31 | Cons. | Operating income |
| Ordinary income | ¥1.5bn | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2020-06-01 → 2021-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2019-06-01 → 2020-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥590m | 2018-06-01 → 2019-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2017-06-01 → 2018-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.3bn | 2021-06-01 → 2022-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2020-06-01 → 2021-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥447m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥426m | 2020-06-01 → 2021-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥577m | 2019-06-01 → 2020-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥23m | 2018-06-01 → 2019-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥28m | 2017-06-01 → 2018-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥458m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss |
| Net income | ¥419m | 2020-06-01 → 2021-05-31 | Cons. | Profit loss |
| Total assets | ¥23.7bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥24.7bn | at 2021-05-31 | Cons. | Assets |
| Total assets | ¥25.2bn | at 2020-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.2bn | at 2019-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.3bn | at 2018-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.0bn | at 2022-05-31 | Cons. | Liabilities |
| Total liabilities | ¥18.4bn | at 2021-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.7bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2021-05-31 | Cons. | Net assets |
| Net assets / equity | ¥5.9bn | at 2020-05-31d | Cons. | Net assets |
| Net assets / equity | ¥5.6bn | at 2019-05-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.6bn | at 2018-05-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.6bn | at 2021-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2021-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2020-05-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2019-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.6bn | at 2018-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥713m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2020-06-01 → 2021-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥895m | 2018-06-01 → 2019-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2017-06-01 → 2018-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥292m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2020-06-01 → 2021-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥734m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥501m | 2018-06-01 → 2019-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥527m | 2017-06-01 → 2018-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥728m | 2020-06-01 → 2021-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥766m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥354m | 2018-06-01 → 2019-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥894m | 2017-06-01 → 2018-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥47.99 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.83 | 2020-06-01 → 2021-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.11 | 2019-06-01 → 2020-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.55 | 2018-06-01 → 2019-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.19 | 2017-06-01 → 2018-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥36.29 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.64 | 2020-06-01 → 2021-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.38 | 2019-06-01 → 2020-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.24 | 2018-06-01 → 2019-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥684.2 | at 2022-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥646.66 | at 2021-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥613.2 | at 2020-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥572.74 | at 2019-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥585.97 | at 2018-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 26.9% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.3% | at 2021-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.6% | at 2020-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.9% | at 2019-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.8% | at 2018-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.2% | 2021-06-01 → 2022-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-06-01 → 2021-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2019-06-01 → 2020-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 0.4% | 2018-06-01 → 2019-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -0.5% | 2017-06-01 → 2018-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,544 | at 2022-05-31 | Cons. | Number of employees |
| Employees | 1,546 | at 2021-05-31 | Cons. | Number of employees |
| Employees | 1,555 | at 2020-05-31d | Cons. | Number of employees |
| Employees | 1,455 | at 2019-05-31d | Cons. | Number of employees |
| Employees | 1,504 | at 2018-05-31d | Cons. | Number of employees |
| Revenue | ¥1.3bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥1.4bn | 2020-06-01 → 2021-05-31 | Standalone | Net sales |
| Revenue | ¥1.2bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥608m | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥618m | 2017-06-01 → 2018-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥304m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Operating income | ¥352m | 2020-06-01 → 2021-05-31 | Standalone | Operating income |
| Ordinary income | ¥406m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥428m | 2020-06-01 → 2021-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥378m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥307m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥366m | 2017-06-01 → 2018-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥208m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥423m | 2020-06-01 → 2021-05-31 | Standalone | Income before income taxes |
| Net income | ¥122m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥320m | 2020-06-01 → 2021-05-31 | Standalone | Profit loss |
| Net income | ¥264m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥229m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥241m | 2017-06-01 → 2018-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥14.6bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥14.9bn | at 2021-05-31 | Standalone | Assets |
| Total assets | ¥15.6bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥15.2bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.8bn | at 2018-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥9.8bn | at 2022-05-31 | Standalone | Liabilities |
| Total liabilities | ¥10.1bn | at 2021-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.8bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.6bn | at 2020-05-31d | Standalone | Net assets |
| Net assets / equity | ¥4.4bn | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2018-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.6bn | at 2022-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2021-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥13.11 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.39 | 2020-06-01 → 2021-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.94 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.1 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.67 | 2017-06-01 → 2018-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥10.03 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.03 | 2020-06-01 → 2021-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.29 | 2019-06-01 → 2020-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.56 | 2018-06-01 → 2019-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥25.79 | 2017-06-01 → 2018-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥14 | 2021-06-01 → 2022-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2020-06-01 → 2021-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2018-06-01 → 2019-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2017-06-01 → 2018-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥492.05 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥490.97 | at 2021-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥470.21 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥459.05 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥445.52 | at 2018-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 31.6% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.7% | at 2021-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.9% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.2% | at 2018-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.7% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2020-06-01 → 2021-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2017-06-01 → 2018-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 9,673,785 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,615,515 | at 2021-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,560,655 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,239,620 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,039,050 | at 2018-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 60 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 33 | at 2021-05-31 | Standalone | Number of employees |
| Employees | 35 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 72 | at 2019-05-31d | Standalone | Number of employees |
| Employees | 76 | at 2018-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 93
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-06-01 → 2022-05-31 | ¥66m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-06-01 → 2022-05-31 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-05-31 | 48 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-06-01 → 2022-05-31 | ¥764m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-06-01 → 2022-05-31 | ¥764m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-05-31 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-06-01 → 2022-05-31 | ¥41m |
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥55m |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-05-31 | −¥294m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2021-06-01 → 2022-05-31 | ¥89m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥44m |
| Cosmetic Drug And Convenience Storereportable segment | employees | at 2022-05-31 | 112 pure |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥7.6bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥7.6bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2022-05-31 | ¥1.9bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2021-06-01 → 2022-05-31 | −¥146m |
| Custody Of Medical Documentsreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥16m |
| Custody Of Medical Documentsreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥41m |
| Custody Of Medical Documentsreportable segment | employees | at 2022-05-31 | 33 pure |
| Custody Of Medical Documentsreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥699m |
| Custody Of Medical Documentsreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥699m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2022-05-31 | ¥2.0bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥107m |
| Dispensing Pharmacyreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥356m |
| Dispensing Pharmacyreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥415m |
| Dispensing Pharmacyreportable segment | employees | at 2022-05-31 | 1204 pure |
| Dispensing Pharmacyreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥42.0bn |
| Dispensing Pharmacyreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥42.0bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2022-05-31 | ¥18.1bn |
| Dispensing Pharmacyreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥1.7bn |
| Medical Mallreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥23m |
| Medical Mallreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥65m |
| Medical Mallreportable segment | employees | at 2022-05-31 | 16 pure |
| Medical Mallreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥503m |
| Medical Mallreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥503m |
| Medical Mallreportable segment | segment assets | at 2022-05-31 | ¥229m |
| Medical Mallreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥67m |
| —segment total | capex | 2021-06-01 → 2022-05-31 | ¥486m |
| —segment total | depreciation | 2021-06-01 → 2022-05-31 | ¥567m |
| —segment total | revenue | 2021-06-01 → 2022-05-31 | ¥50.8bn |
| —segment total | revenue external | 2021-06-01 → 2022-05-31 | ¥50.8bn |
| —segment total | segment assets | at 2022-05-31 | ¥22.2bn |
| —segment total | segment profit | 2021-06-01 → 2022-05-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥552m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥608m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥51.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥51.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥23.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2020-06-01 → 2021-05-31 | ¥37m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2020-06-01 → 2021-05-31 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2020-06-01 → 2021-05-31 | ¥716m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2020-06-01 → 2021-05-31 | ¥716m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2021-05-31 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2020-06-01 → 2021-05-31 | ¥40m |
| Reconciling Itemsreconciling | segment assets | at 2021-05-31 | ¥56m |
| Reconciling Itemsreconciling | segment profit | 2020-06-01 → 2021-05-31 | −¥320m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2020-06-01 → 2021-05-31 | ¥39m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥42m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥8.0bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥8.0bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2021-05-31 | ¥2.0bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2020-06-01 → 2021-05-31 | −¥42m |
| Custody Of Medical Documentsreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥4m |
| Custody Of Medical Documentsreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥41m |
| Custody Of Medical Documentsreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥622m |
| Custody Of Medical Documentsreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥622m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2021-05-31 | ¥2.4bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2020-06-01 → 2021-05-31 | ¥64m |
| Dispensing Pharmacyreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥698m |
| Dispensing Pharmacyreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥410m |
| Dispensing Pharmacyreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥42.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥42.5bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2021-05-31 | ¥18.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2020-06-01 → 2021-05-31 | ¥1.4bn |
| Medical Mallreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥1m |
| Medical Mallreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥64m |
| Medical Mallreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥491m |
| Medical Mallreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥491m |
| Medical Mallreportable segment | segment assets | at 2021-05-31 | ¥278m |
| Medical Mallreportable segment | segment profit | 2020-06-01 → 2021-05-31 | ¥60m |
| —segment total | capex | 2020-06-01 → 2021-05-31 | ¥743m |
| —segment total | depreciation | 2020-06-01 → 2021-05-31 | ¥559m |
| —segment total | revenue | 2020-06-01 → 2021-05-31 | ¥51.6bn |
| —segment total | revenue external | 2020-06-01 → 2021-05-31 | ¥51.6bn |
| —segment total | segment assets | at 2021-05-31 | ¥23.1bn |
| —segment total | segment profit | 2020-06-01 → 2021-05-31 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-06-01 → 2021-05-31 | ¥780m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-06-01 → 2021-05-31 | ¥606m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-06-01 → 2021-05-31 | ¥52.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-06-01 → 2021-05-31 | ¥52.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-05-31 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-06-01 → 2021-05-31 | ¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,583
| Item | Context | Value | Unit |
|---|---|---|---|
| Directors compensations sga | CurrentYearDuration_NonConsolidatedMember | 235000000 | JPY |
| Salaries and allowances oecna | Prior1YearDuration_NonConsolidatedMember | 224000000 | JPY |
| Salaries and allowances oecna | CurrentYearDuration_NonConsolidatedMember | 193000000 | JPY |
| Commission fee sga | Prior1YearDuration_NonConsolidatedMember | 154000000 | JPY |
| Commission fee sga | CurrentYearDuration_NonConsolidatedMember | 109000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-26 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第36期(自 令和３年６月１日 至 令和４年５月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ファーマライズホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Ｐｈａｒｍａｒｉｓｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 社長 秋 山 昌 之 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中野区中央一丁目38番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03-3362-7130（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 沼 田 豊 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中野区中央一丁目38番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03-3362-7130（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 沼 田 豊 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05379 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 27960 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ファーマライズホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Pharmarise Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2021-06-01 | |
| Current period end date | FilingDateInstant | 2022-05-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2022-05-31 | |
| Previous fiscal year start date | FilingDateInstant | 2020-06-01 | |
| Comparative period end date | FilingDateInstant | 2021-05-31 | |
| Previous fiscal year end date | FilingDateInstant | 2021-05-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |